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Toxicity of Autologous
Transplants?
Erythropoietin (EPO) regulates the growth and
production of redblood cells (RBCs) [1,2] andhas pleo-
morphic effects on apoptosis and the regulation of vas-
cular integrity [3]. Randomized, placebo-controlled
trials have demonstrated the benefits of recombinant
human EPO (rHuEPO) to increase Hb levels, reduce
transfusion requirements, and improve quality of life
in anemic cancer patients undergoing chemotherapy
[1,4,5]. Interestingly, rHuEPO also may provide a sur-
vival benefit for patients with multiple myeloma (MM)
through beneficial changes in immune function [1,6].
Furthermore, rHuEPO can increase the number of cir-
culating vascular progenitors andmay play a role in the
repair of ischemic tissue injury, such as myocardial in-
farction and stroke [3]. Anemia before allogeneic he-
matopoietic stem cell transplantation (HSCT) has
been associated with increased transfusion require-
ments and increased treatment-related mortality
(TRM) [7]. More recently, we have found that anemia
on the day of peripheral blood progenitor cell (PBPC)
collection influences graft content of vascular progen-
itors and is associated with increased toxicity after au-
tologous HSCT [8]. Herein we provide new insight
on the possible effect of concomitant rHuEPO therapy
during themobilization of PBPCs in patients withMM
undergoing autologous HSCT.
Once the study was approved by our Institutional
Ethics Review Board, informed consent was obtained
from all patients for analysis of medical information.
A total of 124 participating patients underwent autol-
ogous HSCT to treat MM between August 1994 and
February 2006 at our hospital. The mean age of the
patients was 58 years (range, 33-69 years), and all pa-
tients had symptomatic disease requiring systemic
chemotherapy (see Table 1). Seven patients received
rHuEPO during pretransplantation chemotherapy cy-
cles and throughout the period of mobilization and132collection of autologous PBPCs, 5 patients received
rHuEPO at some point during pretransplantation che-
motherapy but not during the PBPC mobilization pe-
riod, and 112 patients did not receive rHuEPO at any
time before transplantation. Data were extracted from
patient medical records, and transplantation-specific
outcomes were retrieved from The Ottawa Hospital
Blood & Marrow Transplant Program clinical data-
base.
Patients who received rHuEPO during the PBPC
mobilization phase had a lower Hb level at diagnosis
compared with patients who did not receive rHuEPO
(92 g/L vs 108 g/L; P 5 .04) (see Table 2). However,
on the date of the first PBPC collection, the hemoglo-
bin (Hb) levels in both groups were notably similar
(110 vs 107 g/L; P 5 .54) with a significantly higher
relative increase in Hb in patients receiving rHuEPO
(20% increase vs no change in patients who did not re-
ceive EPO; P\ .05). We suggest that EPO may have
contributed to the substantial increase in Hb levels at
PBPC collection. Interestingly, the clinical toxicity
after HSCT was similar in both groups. Moreover,
there was an observed trend toward decreased transfu-
sion of packed red blood cells (PRBCs) in the group
who received rHuEPO (2.6 vs 3.2 units; P 5 .41).
We recognize that multiple factors may have influ-
enced the decision to administer rHuEPO in the small
subset of patients analyzed in this cohort. Furthermore,
it remains unclear how anemia at diagnosis is related
to Hb levels at PBPC collection. In fact, a subset of
patients withHb\100 g/L at diagnosis and who never
received rHuEPOhad similarHb values at diagnosis as
the group of patients who received rHuEPO (85.4 vs
92.6 g/L; P5 .11). Comparing these 2 groups demon-
strated no significant difference in Hb values at PBPC
Table 1. Cohort characteristics
Patient characteristics (n 5 124)
Age at transplantation, years, mean (range) 58 (33-69)
Sex, female/male (%) 53/71 (43/57)
Salmon and Durie stage, n (%)
I 27 (22)
II 18 (15)
III 72 (58)
Unknown 7 (6)
Graft CD341  106 cells/kg, mean 7.3 ± 4.8
Days to absolute neutrophil count recovery, mean 15.6 ± 33.4
Days to platelet recovery, mean 15.5 ± 15.2
Total length of stay, days, mean 21.0 ± 9.3
Patients requiring intensive care, n (%) 3 (2.4%)
Transplantation-related mortality at day 100, n (%) 1 (0.8%)
All means are 6 1 standard deviation.
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EPO patients Non-EPO patients P value
N 7 112
Total length of stay, days, mean 22.0 ± 6.7 20.7 ± 8.9 .63
Patients with any organ toxicity, n (%) 6 (86) 87 (78) .95
Patients with high organ toxicity, n (%) 3 (43) 49 (44) .99
Mean Hb at diagnosis, g/L 92.6 ± 9.2 108.8 ± 20.9 .002
Mean Hb on day of collection, g/L 110.1 ± 11.5 107.2 ± 12.8 .54
Mean Hb before transplantation, g/L 110.6 ± 15.6 110.4 ± 14.4 .98
Mean PRBC units transfused 2.6 ± 1.9 3.2 ± 2.8 .41
NS indicates not significant.
High organ toxicity is $ 2 cumulative grades in all organs by the Seattle criteria.
All means were compared using Student’s t-test, and proportions were compared used c2 analysis.collection and no observed difference in toxicity after
HSCT. The potential influence of concomitant medi-
cations, performance status, and other factors could
not be further assessed in our retrospective analysis.
A study by Hunault-Berger et al. [9], in which
rHuEPO was administered with chemotherapy cycles
before autologous transplantation in a cohort of ane-
mic patients with MM, found that these patients
required fewer PRBC transfusions compared with
patients who were not given rHuEPO. In addition,
rhuEPO-treated patients had reduced lengths of hospi-
tal stay. In their study, however, patients did not receive
rHuEPO during the mobilization of PBPCs. Several
studies addressing the addition of rHuEPO to the mo-
bilization of PBPCs have not assessed toxicity patterns
after transplantation. We hypothesize that continuing
rHuEPO during the mobilization and collection of
PBPCsmay influence the graft content of vascular pro-
genitors, and we have observed that reinfusion of grafts
enriched for vascular progenitors is associated with re-
duced transplantation-related toxicity [10].
Our results suggest that rhuEPO may be a useful
adjunct to increase the regenerative capacity of hema-
topoietic stem cell grafts and may play a role in pre-
venting toxic organ injury after HSCT.
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